Associate Professor of Medicine, Part-time
Integration of Conservative Surgery, Radiotherapy, and Chemotherapy for Patients With Early-Stage Breast Cancer. Semin Radiat Oncol. 1992 Apr; 2(2):107-115.
Integration of Conservative Surgery, Radiotherapy, and Chemotherapy for Patients With Early-Stage Breast Cancer.
Buzdar AU, Come SE, Brodie A, Ellis M, Goss PE, Ingle JN, Johnston SR, Lee AV, Osborne CK, Vogel VG, Hart CS
Clinical cancer research : an official journal of the American Association for Cancer Research
Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4335s-4337s; discussion 4411s-4412s.
Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement.
Park EM, Gelber S, Rosenberg SM, Seah DSE, Schapira L, Come SE, Partridge AH
Anxiety and Depression in Young Women With Metastatic Breast Cancer: A Cross-Sectional Study. Psychosomatics. 2018 May - Jun; 59(3):251-258.
Anxiety and Depression in Young Women With Metastatic Breast Cancer: A Cross-Sectional Study.
Surface remodelling of reticulocytes produced in response to erythroid stress. Nat New Biol. 1972 Apr 05; 236(66):157-8.
Surface remodelling of reticulocytes produced in response to erythroid stress.
Pesando JM, Come SE, Stark J, Parker LM, Griffiths CT, Canellos GP
cis-Diamminedichloroplatinum(II) therapy for advanced ovarian cancer. Cancer Treat Rep. 1980 Oct-Nov; 64(10-11):1147-8.
cis-Diamminedichloroplatinum(II) therapy for advanced ovarian cancer.
Come PC, Come SE, Hawley CR, Gwon N, Riley MF
Echocardiographic manifestations of carcinoid heart disease. J Clin Ultrasound. 1982 May-Jun; 10(5):233-7.
Echocardiographic manifestations of carcinoid heart disease.
Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 2003 Jul 15; 98(2):229-38.
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Invasive pulmonary aspergillosis in an apparently nonimmunocompromised host. Am J Med. 1980 Oct; 69(4):624-7.
Invasive pulmonary aspergillosis in an apparently nonimmunocompromised host.
Recht A, Schnitt SJ, Connolly JL, Rose MA, Silver B, Come S, Henderson IC, Slavin S, Harris JR
International journal of radiation oncology, biology, physics
Prognosis following local or regional recurrence after conservative surgery and radiotherapy for early stage breast carcinoma. Int J Radiat Oncol Biol Phys. 1989 Jan; 16(1):3-9.
Prognosis following local or regional recurrence after conservative surgery and radiotherapy for early stage breast carcinoma.
Recht A, Connolly JL, Schnitt SJ, Cady B, Love S, Osteen RT, Patterson WB, Shirley R, Silen W, Come S
Conservative surgery and radiation therapy for early breast cancer: results, controversies, and unsolved problems. Semin Oncol. 1986 Dec; 13(4):434-49.
Conservative surgery and radiation therapy for early breast cancer: results, controversies, and unsolved problems.
Henderson IC, Hayes DF, Come S, Harris JR, Canellos G
New agents and new medical treatments for advanced breast cancer. Semin Oncol. 1987 Mar; 14(1):34-64.
New agents and new medical treatments for advanced breast cancer.
Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol. 1990 Apr; 8(4):648-56.
Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
Ensminger WD, Thompson M, Come S, Egan EM
Hepatic arterial BCNU: a pilot clinical-pharmacologic study in patients with liver tumors. Cancer Treat Rep. 1978 Oct; 62(10):1509-12.
Hepatic arterial BCNU: a pilot clinical-pharmacologic study in patients with liver tumors.
Uematsu M, Bornstein BA, Recht A, Abner A, Come SE, Shulman LN, Silver B, Harris JR
Long-term results of post-operative radiation therapy following mastectomy with or without chemotherapy in stage I-III breast cancer. Int J Radiat Oncol Biol Phys. 1993 Apr 02; 25(5):765-70.
Long-term results of post-operative radiation therapy following mastectomy with or without chemotherapy in stage I-III breast cancer.
Morris PG, Chen C, Steingart R, Fleisher M, Lin N, Moy B, Come S, Sugarman S, Abbruzzi A, Lehman R, Patil S, Dickler M, McArthur HL, Winer E, Norton L, Hudis CA, Dang CT
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res. 2011 May 15; 17(10):3490-9.
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.
Robertson JF, Erikstein B, Osborne KC, Pippen J, Come SE, Parker LM, Gertler S, Harrison MP, Clarke DA
Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. Clin Pharmacokinet. 2004; 43(8):529-38.
Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer.
Kaplan WD, Come SE, Takvorian RW, Laffin SM, Gelman RS, Weiss GR, Garnick MB
Pulmonary uptake of technetium 99m macroaggregated albumin: a predictor of gastrointestinal toxicity during hepatic artery perfusion. J Clin Oncol. 1984 Nov; 2(11):1266-9.
Pulmonary uptake of technetium 99m macroaggregated albumin: a predictor of gastrointestinal toxicity during hepatic artery perfusion.
Wong JS, Recht A, Beard CJ, Busse PM, Cady B, Chaffey JT, Come S, Fam S, Kaelin C, Lingos TI, Nixon AJ, Shulman LN, Troyan S, Silver B, Harris JR
Treatment outcome after tangential radiation therapy without axillary dissection in patients with early-stage breast cancer and clinically negative axillary nodes. Int J Radiat Oncol Biol Phys. 1997 Nov 01; 39(4):915-20.
Treatment outcome after tangential radiation therapy without axillary dissection in patients with early-stage breast cancer and clinically negative axillary nodes.
Sequencing of irradiation and chemotherapy for early-stage breast cancer. Oncology (Williston Park). 1994 Mar; 8(3):19-28; discussion 28, 31-2, 37.
Sequencing of irradiation and chemotherapy for early-stage breast cancer.
Abner AL, Recht A, Eberlein T, Come S, Shulman L, Hayes D, Connolly JL, Schnitt SJ, Silver B, Harris JR
Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol. 1993 Jan; 11(1):44-8.
Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer.
Come PC, Come SE, Riley MF, Carl LV, Nakao S
Reversible right ventricular outflow tract compression by immunoblastic sarcoma. Am J Cardiol. 1985 Jan 01; 55(1):239-40.
Reversible right ventricular outflow tract compression by immunoblastic sarcoma.
Adjuvant chemotherapy for breast cancer. Compr Ther. 1980 Oct; 6(10):42-7.
Adjuvant chemotherapy for breast cancer.
Mauch P, Leonard R, Skarin A, Rosenthal D, Come S, Chaffey J, Hellman S, Canellos G
Improved survival following combined radiation therapy and chemotherapy for unfavorable prognosis stage I-II non-Hodgkin's lymphomas. J Clin Oncol. 1985 Oct; 3(10):1301-8.
Improved survival following combined radiation therapy and chemotherapy for unfavorable prognosis stage I-II non-Hodgkin's lymphomas.
Come SE, Jaffe ES, Andersen JC, Mann RB, Johnson BL, DeVita VT, Young RC
Non-Hodgkin's lymphomas in leukemic phase: clinicopathologic correlations. Am J Med. 1980 Nov; 69(5):667-74.
Non-Hodgkin's lymphomas in leukemic phase: clinicopathologic correlations.
Mauch PM, Canellos GP, Shulman LN, Silver B, Tarbell NJ, Come S, Rabin MS, Coleman CN
Mantle irradiation alone for selected patients with laparotomy-staged IA to IIA Hodgkin's disease: preliminary results of a prospective trial. J Clin Oncol. 1995 Apr; 13(4):947-52.
Mantle irradiation alone for selected patients with laparotomy-staged IA to IIA Hodgkin's disease: preliminary results of a prospective trial.
Come SE, Buzdar AU, Ingle JN, Johnston SRD, Brodie AM, Coombes RC, Miller WR, Pritchard KI, Winer EP, Zujewski JA, Goss PE
Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference. Cancer. 2008 Feb 01; 112(3 Suppl):673-678.
Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.
Greenberger JS, Come SE, Weichselbaum RR
Issues of controversy in radiation therapy and combined modality approaches to Hodgkin's disease. Clin Haematol. 1979 Oct; 8(3):611-24.
Issues of controversy in radiation therapy and combined modality approaches to Hodgkin's disease.
Recht A, Come SE, Henderson IC, Gelman RS, Silver B, Hayes DF, Shulman LN, Harris JR
The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med. 1996 May 23; 334(21):1356-61.
The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer.
von Hippel C, Rosenberg SM, Austin SB, Sprunck-Harrild K, Ruddy KJ, Schapira L, Come S, Borges VF, Partridge AH
Identifying distinct trajectories of change in young breast cancer survivors' sexual functioning. Psychooncology. 2019 05; 28(5):1033-1040.
Identifying distinct trajectories of change in young breast cancer survivors' sexual functioning.
Interdisciplinary Medicine and Biotechnology
Wassermann J, Gelber SI, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, Borges VF, Come SE, Meyer ME, Partridge AH
Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer. Cancer. 2019 09 15; 125(18):3266-3274.
Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer.
Rath M, Li Q, Li H, Lindström S, Miron A, Miron P, Dowton AE, Meyer ME, Larson BG, Pomerantz M, Seo JH, Collins LC, Vardeh H, Brachtel E, Come SE, Borges V, Schapira L, Tamimi RM, Partridge AH, Freedman M, Ruddy KJ
Evaluation of significant genome-wide association studies risk - SNPs in young breast cancer patients. PLoS One. 2019; 14(5):e0216997.
Evaluation of significant genome-wide association studies risk - SNPs in young breast cancer patients.
Rosenberg SM, Vaz-Luis I, Gong J, Rajagopal PS, Ruddy KJ, Tamimi RM, Schapira L, Come S, Borges V, de Moor JS, Partridge AH
Employment trends in young women following a breast cancer diagnosis. Breast Cancer Res Treat. 2019 Aug; 177(1):207-214.
Employment trends in young women following a breast cancer diagnosis.
Theodore W. and Evelyn G. Berenson Distinguished Professor of Medicine in the Field of Oncology
Mayer EL, DeMichele A, Rugo HS, Miller K, Waks AG, Come SE, Mulvey T, Jeselsohn R, Overmoyer B, Guo H, Barry WT, Huang Bartlett C, Koehler M, Winer EP, Burstein HJ
Annals of oncology : official journal of the European Society for Medical Oncology
A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019 09 01; 30(9):1514-1520.
A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.
Lee GE, Rosenberg SM, Mayer EL, Borges V, Meyer ME, Schapira L, Come SE, Partridge AH
Contemporary management of breast cancer during pregnancy and subsequent lactation in a multicenter cohort of young women with breast cancer. Breast J. 2019 11; 25(6):1104-1110.
Contemporary management of breast cancer during pregnancy and subsequent lactation in a multicenter cohort of young women with breast cancer.
Poorvu PD, Gelber SI, Rosenberg SM, Ruddy KJ, Tamimi RM, Collins LC, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E, Jakubowski DM, Russell C, Winer EP, Partridge AH
Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer. J Clin Oncol. 2020 03 01; 38(7):725-733.
Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.
A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019 Sep; 30(9):1514-1520.
Seah DS, Scott SM, Najita J, Openshaw T, Krag K, Frank E, Sohl J, Stadler ZK, Garrett M, Silverman SG, Peppercorn J, Winer EP, Come SE, Lin NU
Attitudes of patients with metastatic breast cancer toward research biopsies. Ann Oncol. 2013 Jul; 24(7):1853-1859.
Attitudes of patients with metastatic breast cancer toward research biopsies.
Rath M, Li Q, Li H, Lindström S, Miron A, Miron P, Dowton AA, Meyer ME, Larson BG, Pomerantz M, Seo JH, Collins LC, Vardeh H, Brachtel E, Come SE, Borges V, Schapira L, Tamimi RM, Partridge AH, Freedman M, Ruddy KJ
Correction: Evaluation of significant genome-wide association studies risk-SNPs in young breast cancer patients. PLoS One. 2020; 15(3):e0230529.
Correction: Evaluation of significant genome-wide association studies risk-SNPs in young breast cancer patients.
Jeselsohn RM, Werner L, Regan MM, Fatima A, Gilmore L, Collins LC, Beck AH, Bailey ST, He HH, Buchwalter G, Brown M, Iglehart JD, Richardson A, Come SE
Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune response. PLoS One. 2013; 8(5):e64225.
Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune response.
Xu J, Higgins MJ, Tolaney SM, Come SE, Smith MR, Fornier M, Mahmood U, Baselga J, Yeap BY, Chabner BA, Isakoff SJ
A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases. Oncologist. 2020 08; 25(8):652-660.
A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases.
Vazquez D, Rosenberg S, Gelber S, Ruddy KJ, Morgan E, Recklitis C, Come S, Schapira L, Partridge AH
Posttraumatic stress in breast cancer survivors diagnosed at a young age. Psychooncology. 2020 08; 29(8):1312-1320.
Posttraumatic stress in breast cancer survivors diagnosed at a young age.
Rosenberg SM, Dominici LS, Gelber S, Poorvu PD, Ruddy KJ, Wong JS, Tamimi RM, Schapira L, Come S, Peppercorn JM, Borges VF, Partridge AH
Association of Breast Cancer Surgery With Quality of Life and Psychosocial Well-being in Young Breast Cancer Survivors. JAMA Surg. 2020 11 01; 155(11):1035-1042.
Association of Breast Cancer Surgery With Quality of Life and Psychosocial Well-being in Young Breast Cancer Survivors.
Borstelmann NA, Rosenberg S, Gelber S, Zheng Y, Meyer M, Ruddy KJ, Schapira L, Come S, Borges V, Cadet T, Maramaldi P, Partridge AH
Partners of young breast cancer survivors: a cross-sectional evaluation of psychosocial concerns, coping, and mental health. J Psychosoc Oncol. 2020 Nov-Dec; 38(6):670-686.
Partners of young breast cancer survivors: a cross-sectional evaluation of psychosocial concerns, coping, and mental health.
Filho OM, Giobbie-Hurder A, Lin NU, Faggen M, Come S, Openshaw T, Constantine M, Walsh J, Freedman RA, Schneider B, Burstein HJ, Mayer EL
A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer. Breast Cancer Res Treat. 2021 Jan; 185(1):135-144.
A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer.
Sella T, Gelber SI, Poorvu PD, Kim HJ, Dominici L, Guzman-Arocho YD, Collins L, Ruddy KJ, Tamimi RM, Peppercorn JM, Schapira L, Borges VF, Come SE, Warner E, Snow C, Jakubowski DM, Russell CA, Winer EP, Rosenberg SM, Partridge AH
Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat. 2021 Feb; 186(1):157-165.
Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer.
Pak LM, Gaither R, Rosenberg SM, Ruddy KJ, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E, Snow C, Collins LC, King TA, Partridge AH
Tumor phenotype and concordance in synchronous bilateral breast cancer in young women. Breast Cancer Res Treat. 2021 Apr; 186(3):815-821.
Tumor phenotype and concordance in synchronous bilateral breast cancer in young women.
Poorvu PD, Gelber SI, Zheng Y, Ruddy KJ, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Lambertini M, Rosenberg SM, Partridge AH
Pregnancy after breast cancer: Results from a prospective cohort of young women with breast cancer. Cancer. 2021 04 01; 127(7):1021-1028.
Pregnancy after breast cancer: Results from a prospective cohort of young women with breast cancer.
Seah DS, Leone JP, Openshaw TH, Scott SM, Tayob N, Hu J, Lederman RI, Frank ES, Sohl JJ, Stadler ZK, Erick TK, Silverman SG, Peppercorn JM, Winer EP, Come SE, Lin NU
Perceptions of patients with early stage breast cancer toward research biopsies. Cancer. 2021 04 15; 127(8):1208-1219.
Perceptions of patients with early stage breast cancer toward research biopsies.
Kim HJ, Dominici L, Rosenberg SM, Zheng Y, Pak LM, Poorvu PD, Ruddy KJ, Tamimi R, Schapira L, Come SE, Peppercorn J, Borges VF, Warner E, Vardeh H, Collins LC, Gaither R, King TA, Partridge AH
Surgical Treatment After Neoadjuvant Systemic Therapy in Young Women With Breast Cancer: Results From a Prospective Cohort Study. Ann Surg. 2022 07 01; 276(1):173-179.
Surgical Treatment After Neoadjuvant Systemic Therapy in Young Women With Breast Cancer: Results From a Prospective Cohort Study.
Sella T, Poorvu PD, Ruddy KJ, Gelber SI, Tamimi RM, Peppercorn JM, Schapira L, Borges VF, Come SE, Partridge AH, Rosenberg SM
Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors. Cancer. 2021 08 15; 127(16):2888-2894.
Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors.
Kuijer A, Dominici LS, Rosenberg SM, Hu J, Gelber S, Di Lascio S, Wong JS, Ruddy KJ, Tamimi RM, Schapira L, Borges VF, Come SE, Sprunck-Harrild K, Partridge AH, King TA
Arm Morbidity After Local Therapy for Young Breast Cancer Patients. Ann Surg Oncol. 2021 Oct; 28(11):6071-6082.
Arm Morbidity After Local Therapy for Young Breast Cancer Patients.
Moy B, Rumble RB, Come SE, Davidson NE, Di Leo A, Gralow JR, Hortobagyi GN, Yee D, Smith IE, Chavez-MacGregor M, Nanda R, McArthur HL, Spring L, Reeder-Hayes KE, Ruddy KJ, Unger PS, Vinayak S, Irvin WJ, Armaghani A, Danso MA, Dickson N, Turner SS, Perkins CL, Carey LA
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. J Clin Oncol. 2021 12 10; 39(35):3938-3958.
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
Poorvu PD, Hu J, Zheng Y, Gelber SI, Ruddy KJ, Tamimi RM, Peppercorn JM, Schapira L, Borges VF, Come SE, Warner E, Lambertini M, Rosenberg SM, Partridge AH
Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer. NPJ Breast Cancer. 2021 Jul 27; 7(1):99.
Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer.
Dominici L, Hu J, Zheng Y, Kim HJ, King TA, Ruddy KJ, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E, Wong JS, Partridge AH, Rosenberg SM
Association of Local Therapy With Quality-of-Life Outcomes in Young Women With Breast Cancer. JAMA Surg. 2021 10 01; 156(10):e213758.
Association of Local Therapy With Quality-of-Life Outcomes in Young Women With Breast Cancer.
Schapira L, Zheng Y, Gelber SI, Poorvu P, Ruddy KJ, Tamimi RM, Peppercorn J, Come SE, Borges VF, Partridge AH, Rosenberg SM
Trajectories of fear of cancer recurrence in young breast cancer survivors. Cancer. 2022 Jan 15; 128(2):335-343.
Trajectories of fear of cancer recurrence in young breast cancer survivors.
Guzmán-Arocho YD, Rosenberg SM, Garber JE, Vardeh H, Poorvu PD, Ruddy KJ, Kirkner G, Snow C, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Brachtel EF, Marotti JD, Warner E, Partridge AH, Collins LC
Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. Br J Cancer. 2022 02; 126(2):302-309.
Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer.
Seah DS, Tayob N, Leone JP, Hu J, Yin J, Hughes M, Scott SM, Lederman RI, Frank E, Sohl JJ, Stadler ZK, Erick TK, Peppercorn J, Winer EP, Silverman SG, Come SE, Lin NU
Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings. Breast Cancer Res Treat. 2022 Feb; 192(1):201-210.
Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings.
Borstelmann NA, Gray TF, Gelber S, Rosenberg S, Zheng Y, Meyer M, Ruddy KJ, Schapira L, Come S, Borges V, Cadet T, Maramaldi P, Partridge AH
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Psychosocial issues and quality of life of parenting partners of young women with breast cancer. Support Care Cancer. 2022 May; 30(5):4265-4274.
Psychosocial issues and quality of life of parenting partners of young women with breast cancer.
Waks AG, Kim D, Jain E, Snow C, Kirkner GJ, Rosenberg SM, Oh C, Poorvu PD, Ruddy KJ, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Brachtel EF, Warner E, Collins LC, Partridge AH, Wagle N
Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer. Clin Cancer Res. 2022 06 01; 28(11):2339-2348.
Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer.
Sella T, Zheng Y, Tan-Wasielewski Z, Rosenberg SM, Poorvu PD, Tayob N, Ruddy KJ, Gelber SI, Tamimi RM, Schapira L, Come SE, Peppercorn JM, Borges VF, Partridge AH, Ligibel JA
Body weight changes and associated predictors in a prospective cohort of young breast cancer survivors. Cancer. 2022 09 01; 128(17):3158-3169.
Body weight changes and associated predictors in a prospective cohort of young breast cancer survivors.
Krasne M, Ruddy KJ, Poorvu PD, Gelber SI, Tamimi RM, Schapira L, Peppercorn J, Come SE, Borges VF, Partridge AH, Rosenberg SM
Coping strategies and anxiety in young breast cancer survivors. Support Care Cancer. 2022 Nov; 30(11):9109-9116.
Coping strategies and anxiety in young breast cancer survivors.
Tesch ME, Rosenberg SM, Collins LC, Wong JS, Dominici L, Ruddy KJ, Tamimi R, Schapira L, Borges VF, Warner E, Come SE, Partridge AH
ASO Visual Abstract: Clinicopathologic Features, Treatment Patterns, and Disease Outcomes in a Modern, Prospective Cohort of Young Women Diagnosed with Ductal Carcinoma In Situ. Ann Surg Oncol. 2022 Dec; 29(13):8058-8059.
ASO Visual Abstract: Clinicopathologic Features, Treatment Patterns, and Disease Outcomes in a Modern, Prospective Cohort of Young Women Diagnosed with Ductal Carcinoma In Situ.
Sella T, Fell GG, Miller PG, Gibson CJ, Rosenberg SM, Snow C, Stover DG, Ruddy KJ, Peppercorn JM, Schapira L, Borges VF, Come SE, Warner E, Frank E, Neuberg DS, Ebert BL, Partridge AH
Patient perspectives on testing for clonal hematopoiesis of indeterminate potential. Blood Adv. 2022 12 27; 6(24):6151-6161.
Patient perspectives on testing for clonal hematopoiesis of indeterminate potential.
Clinicopathologic Features, Treatment Patterns, and Disease Outcomes in a Modern, Prospective Cohort of Young Women Diagnosed with Ductal Carcinoma In Situ. Ann Surg Oncol. 2022 Dec; 29(13):8048-8057.
Clinicopathologic Features, Treatment Patterns, and Disease Outcomes in a Modern, Prospective Cohort of Young Women Diagnosed with Ductal Carcinoma In Situ.
Rosenberg SM, Zheng Y, Gelber S, Ruddy KJ, Poorvu P, Sella T, Tamimi RM, Wassermann J, Schapira L, Borges VF, Come S, Peppercorn J, Sepucha KR, Partridge AH
Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer. Breast Cancer Res Treat. 2023 Feb; 197(3):547-558.
Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer.
Lewinsohn R, Zheng Y, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, Peppercorn J, Borges VF, Come S, Snow C, Ginsburg ES, Partridge AH
Fertility Preferences and Practices Among Young Women With Breast Cancer: Germline Genetic Carriers Versus Noncarriers. Clin Breast Cancer. 2023 04; 23(3):317-323.
Fertility Preferences and Practices Among Young Women With Breast Cancer: Germline Genetic Carriers Versus Noncarriers.
Lipsyc-Sharf M, Jain E, Collins LC, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, Come SE, Peppercorn JM, Borges VF, Warner E, Snow C, Krop IE, Kim D, Weiss J, Zanudo JGT, Partridge AH, Wagle N, Waks AG
Genomics of ERBB2-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab. JCO Precis Oncol. 2023 06; 7:e2300076.
Genomics of ERBB2-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab.
Sella T, Zheng Y, Rosenberg SM, Ruddy KJ, Gelber SI, Tamimi RM, Peppercorn JM, Schapira L, Borges VF, Come SE, Carey LA, Winer EP, Partridge AH
Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors. NPJ Breast Cancer. 2023 Apr 25; 9(1):31.
Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors.
Sorouri K, Sella T, Rosenberg SM, Loucks M, Kirkner G, Snow C, Ruddy KJ, Gelber SI, Tamimi RM, Peppercorn JM, Schapira L, Borges VF, Come SE, Warner E, Partridge AH
Conception and pregnancy among women with a live birth after breast cancer treatment: A survey study of young breast cancer survivors. Cancer. 2024 02 15; 130(4):517-529.
Conception and pregnancy among women with a live birth after breast cancer treatment: A survey study of young breast cancer survivors.
Brantley KD, Rosenberg SM, Collins LC, Ruddy KJ, Tamimi RM, Schapira L, Borges VF, Warner E, Come SE, Zheng Y, Kirkner GJ, Snow C, Winer EP, Partridge AH
Second Primary Breast Cancer in Young Breast Cancer Survivors. JAMA Oncol. 2024 06 01; 10(6):718-725.
Second Primary Breast Cancer in Young Breast Cancer Survivors.
Zhang BX, Brantley KD, Rosenberg SM, Kirkner GJ, Collins LC, Ruddy KJ, Tamimi RM, Schapira L, Borges VF, Warner E, Come SE, Winer EP, Bellon JR, Partridge AH
Second primary non-breast cancers in young breast cancer survivors. Breast Cancer Res Treat. 2024 Oct; 207(3):587-597.
Second primary non-breast cancers in young breast cancer survivors.
Rosenberg SM, Zheng Y, Ruddy K, Poorvu PD, Snow C, Kirkner GJ, Meyer ME, Tamimi RM, Schapira L, Peppercorn J, Come S, Borges VF, Warner E, Gelber S, Collins L, Winer EP, Partridge AH
Helping ourselves, helping others: the Young Women's Breast Cancer Study (YWS) - a multisite prospective cohort study to advance the understanding of breast cancer diagnosed in women aged 40 years and younger. BMJ Open. 2024 07 01; 14(6):e081157.
Helping ourselves, helping others: the Young Women's Breast Cancer Study (YWS) - a multisite prospective cohort study to advance the understanding of breast cancer diagnosed in women aged 40 years and younger.
Vo JB, Rosenberg S, Zhang BX, Snow C, Kirkner G, Poorvu PD, Gaither R, Ruddy KJ, Tamimi RM, Peppercorn JM, Schapira L, Borges VF, Come SE, Nohria A, Partridge AH
Journal of cancer survivorship : research and practice
Association of cancer treatment with excess heart age among five-year young breast cancer survivors. J Cancer Surviv. 2026 Feb; 20(1):189-197.
Association of cancer treatment with excess heart age among five-year young breast cancer survivors.
Tesch ME, Zheng Y, Rosenberg SM, Poorvu PD, Ruddy KJ, Tamimi R, Schapira L, Peppercorn J, Borges V, Come SE, Snow C, Bhasin S, Partridge AH
Estrogen levels in young women with hormone receptor-positive breast cancer on ovarian function suppression therapy. NPJ Breast Cancer. 2024 Aug 01; 10(1):67.
Estrogen levels in young women with hormone receptor-positive breast cancer on ovarian function suppression therapy.
Lin NU, Seah DS, Gelman R, Desantis S, Mayer EL, Isakoff S, Dipiro P, Krop IE, Come SE, Weckstein D, Winer EP, Burstein HJ
A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Jun; 139(2):403-10.
A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer.
Rosenberg SM, Tamimi RM, Gelber S, Ruddy KJ, Kereakoglow S, Borges VF, Come SE, Schapira L, Winer EP, Partridge AH
Body image in recently diagnosed young women with early breast cancer. Psychooncology. 2013 Aug; 22(8):1849-55.
Body image in recently diagnosed young women with early breast cancer.
Sella T, Sorouri K, Rosenberg SM, Loucks M, Kirkner G, Snow C, Ruddy KJ, Gelber SI, Tamimi RM, Peppercorn JM, Schapira L, Borges VF, Come SE, Warner E, Partridge AH
Breastfeeding experiences among young breast cancer survivors: A survey study. Cancer. 2025 Jan 01; 131(1):e35585.
Breastfeeding experiences among young breast cancer survivors: A survey study.
Myers SP, Zheng Y, Dibble K, Mittendorf EA, King TA, Ruddy KJ, Peppercorn JM, Schapira L, Borges VF, Come SE, Rosenberg SM, Partridge AH
Financial Difficulty Over Time in Young Adults With Breast Cancer. JAMA Netw Open. 2024 11 04; 7(11):e2446091.
Financial Difficulty Over Time in Young Adults With Breast Cancer.
Mostofsky E, Buring JE, Come SE, Tung NM, Zhang C, Mukamal KJ
Effect of daily alcohol intake on sex hormone levels among postmenopausal breast cancer survivors on aromatase inhibitor therapy: a randomized controlled crossover pilot study. Breast Cancer Res. 2025 Jan 09; 27(1):5.
Effect of daily alcohol intake on sex hormone levels among postmenopausal breast cancer survivors on aromatase inhibitor therapy: a randomized controlled crossover pilot study.
Rosenberg SM, Tracy MS, Meyer ME, Sepucha K, Gelber S, Hirshfield-Bartek J, Troyan S, Morrow M, Schapira L, Come SE, Winer EP, Partridge AH
Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med. 2013 Sep 17; 159(6):373-81.
Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey.
Trapani D, Jin Q, Miller KD, Rugo HS, Reeder-Hayes KE, Traina T, Abdou Y, Falkson C, Abramson V, Ligibel J, Chen W, Come S, Nohria A, Ryabin N, Tayob N, Tolaney SM, Burstein HJ, Mayer EL
Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical Trials. Clin Breast Cancer. 2025 Jun; 25(4):e419-e430.e5.
Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical Trials.
Lin NU, Freedman RA, Ramakrishna N, Younger J, Storniolo AM, Bellon JR, Come SE, Gelman RS, Harris GJ, Henderson MA, Macdonald SM, Mahadevan A, Eisenberg E, Ligibel JA, Mayer EL, Moy B, Eichler AF, Winer EP
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res Treat. 2013 Nov; 142(2):405-14.
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.
Ruddy KJ, Gelber S, Tamimi RM, Schapira L, Come SE, Meyer ME, Winer EP, Partridge AH
Breast cancer presentation and diagnostic delays in young women. Cancer. 2014 Jan 01; 120(1):20-5.
Breast cancer presentation and diagnostic delays in young women.
Morris PG, Iyengar NM, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger KC, Lin N, Moy B, Come SE, Winer EP, Norton L, Hudis CA, Dang CT
Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. Cancer. 2013 Nov 15; 119(22):3943-51.
Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer.
Ruddy KJ, Gelber SI, Tamimi RM, Ginsburg ES, Schapira L, Come SE, Borges VF, Meyer ME, Partridge AH
Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol. 2014 Apr 10; 32(11):1151-6.
Prospective study of fertility concerns and preservation strategies in young women with breast cancer.
Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gómez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, Sun J, Hawryluk M, Lipson D, Otto G, Ross JS, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt S, Come SE, Pusztai L, Stephens P, Brown M, Miller VA
Emergence of constitutively active estrogen receptor-a mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res. 2014 Apr 01; 20(7):1757-1767.
Emergence of constitutively active estrogen receptor-a mutations in pretreated advanced estrogen receptor-positive breast cancer.
Tolaney SM, Jeong J, Guo H, Brock J, Morganstern D, Come SE, Golshan M, Bellon J, Winer EP, Krop IE
A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer. Cancer Med. 2014 Apr; 3(2):293-9.
A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer.
Sorouri K, Zheng Y, Sella T, Rosenberg SM, Loucks M, Kirkner GJ, Snow C, Ruddy KJ, Gelber SI, Tamimi RM, Peppercorn JM, Schapira L, Borges VF, Come SE, Warner E, Ginsburg ES, Partridge AH
Fertility preservation and fertility treatment use in young breast cancer survivors reporting a live birth. Fertil Steril. 2026 Jan; 125(1):166-168.
Fertility preservation and fertility treatment use in young breast cancer survivors reporting a live birth.
Ssebyala SN, Zheng Y, Riley E, Ruddy KJ, Tamimi RM, Peppercorn JM, Schapira L, Come SE, Borges VF, Partridge AH, Rosenberg SM
Health Care Utilization and Follow-Up Care in Young Adult Breast Cancer Survivors. JCO Oncol Pract. 2025 Sep 24; OP2500288.
Health Care Utilization and Follow-Up Care in Young Adult Breast Cancer Survivors.
Tesch ME, Zheng Y, Guzman-Arocho YD, Collins LC, Heng YJ, Tayob N, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, Peppercorn J, Borges V, Come SE, Snow C, Winer E, Mittendorf EA, Partridge AH
Association of tumor-infiltrating lymphocyte subtypes with clinical characteristics and prognosis in young women with hormone receptor-positive breast cancer. Clin Cancer Res. 2025 10 21.
Association of tumor-infiltrating lymphocyte subtypes with clinical characteristics and prognosis in young women with hormone receptor-positive breast cancer.
Dominici LS, Zheng Y, King TA, Wong J, Ruddy KJ, Tamimi RM, Peppercorn J, Schapira L, Borges V, Come S, Collins LC, Warner E, Partridge AH, Rosenberg SM
Long-Term Locoregional Outcomes in a Contemporary Cohort of Young Women With Breast Cancer. JAMA Surg. 2025 Jul 23.
Long-Term Locoregional Outcomes in a Contemporary Cohort of Young Women With Breast Cancer.
Rosenberg SM, Tamimi RM, Gelber S, Ruddy KJ, Bober SL, Kereakoglow S, Borges VF, Come SE, Schapira L, Partridge AH
Treatment-related amenorrhea and sexual functioning in young breast cancer survivors. Cancer. 2014 Aug 01; 120(15):2264-71.
Treatment-related amenorrhea and sexual functioning in young breast cancer survivors.
Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D, Brundage SB, Danso MA, Wilcox M, Smith IE
Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014 Oct 10; 32(29):3307-29.
Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Chavarri-Guerra Y, Higgins MJ, Szymonifka J, Cigler T, Liedke P, Partridge A, Ligibel J, Come SE, Finkelstein D, Ryan PD, Goss PE
Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy. Br J Cancer. 2014 Nov 25; 111(11):2046-50.
Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy.
Mayer EL, Gropper AB, Harris L, Gold JM, Parker L, Kuter I, Come S, Najita JS, Guo H, Winer EP, Burstein HJ
Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer. Clin Breast Cancer. 2015 Feb; 15(1):24-30.
Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer.
Arendt LM, Keller PJ, Skibinski A, Goncalves K, Naber SP, Buchsbaum RJ, Gilmore H, Come SE, Kuperwasser C
Anatomical localization of progenitor cells in human breast tissue reveals enrichment of uncommitted cells within immature lobules. Breast Cancer Res. 2014 Oct 15; 16(5):453.
Anatomical localization of progenitor cells in human breast tissue reveals enrichment of uncommitted cells within immature lobules.
Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2015 Jun 10; 33(17):1902-9.
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
Collins LC, Gelber S, Marotti JD, White S, Ruddy K, Brachtel EF, Schapira L, Come SE, Borges VF, Schedin P, Warner E, Wensley T, Tamimi RM, Winer EP, Partridge AH
Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. Oncologist. 2015 Jul; 20(7):713-8.
Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women.
Seah DS, Scott S, Guo H, Najita J, Lederman R, Frank E, Sohl J, Stadler Z, Silverman S, Peppercorn J, Winer E, Come S, Lin NU
Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer. Oncologist. 2015 Sep; 20(9):992-1000.
Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer.
Rosenberg SM, Sepucha K, Ruddy KJ, Tamimi RM, Gelber S, Meyer ME, Schapira L, Come SE, Borges VF, Golshan M, Winer EP, Partridge AH
Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer. Ann Surg Oncol. 2015 Nov; 22(12):3809-15.
Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer.
Borstelmann NA, Rosenberg SM, Ruddy KJ, Tamimi RM, Gelber S, Schapira L, Come S, Borges V, Morgan E, Partridge AH
Partner support and anxiety in young women with breast cancer. Psychooncology. 2015 Dec; 24(12):1679-85.
Partner support and anxiety in young women with breast cancer.
Rosenberg SM, Ruddy KJ, Tamimi RM, Gelber S, Schapira L, Come S, Borges VF, Larsen B, Garber JE, Partridge AH
BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer. JAMA Oncol. 2016 Jun 01; 2(6):730-6.
BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.
Bychkovsky BL, Guo H, Sutton J, Spring L, Faig J, Dagogo-Jack I, Battelli C, Houlihan MJ, Yeh TC, Come SE, Lin NU
Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer. Oncologist. 2016 12; 21(12):1495-1501.
Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer.
Shields H, Li J, Pelletier S, Wang H, Freedman R, Mamon H, Ng A, Freedman A, Come S, Avigan D, Huberman M, Recht A
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
Persistence of dysphagia and odynophagia after mediastinal radiation and chemotherapy in patients with lung cancer or lymphoma. Dis Esophagus. 2017 02 01; 30(2):1-8.
Persistence of dysphagia and odynophagia after mediastinal radiation and chemotherapy in patients with lung cancer or lymphoma.
Lin NU, Carey LA, Liu MC, Younger J, Come SE, Bullitt E, Van Den Abbeele AD, Li X, Hochberg FH, Winer EP
Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):503.
Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer.
Ruddy KJ, Gelber S, Tamimi R, Schapira L, Come S, Kereakoglow S, Lin NU, Winer EP, Partridge AH
Presentation of breast cancer in young women. J Clin Oncol. 2009 May 20; 27(15_suppl):6608.
Presentation of breast cancer in young women.
Come SE, Parker LM, Wulf G, Kuter I, Ryan PD, Tkaczuk K, Borges V, Kasper H, Gelman R, Winer EP
Tolerability and efficacy of 500 mg fulvestrant in postmenopausal women with estrogen receptor (ER)+ advanced breast cancer. J Clin Oncol. 2009 May 20; 27(15_suppl):1050.
Tolerability and efficacy of 500 mg fulvestrant in postmenopausal women with estrogen receptor (ER)+ advanced breast cancer.
Cigler T, Higgins MJ, Szymonifka J, Partridge AH, Ligibel JA, Finkelstein D, Come SE, Ryan PD, Goss PE
A phase II clinical trial of drug withdrawal in women with progressive breast cancer while on aromatase inhibitor therapy. J Clin Oncol. 2011 May 20; 29(15_suppl):559.
A phase II clinical trial of drug withdrawal in women with progressive breast cancer while on aromatase inhibitor therapy.
Isakoff SJ, Goss PE, Mayer EL, Traina TA, Carey LA, Krag K, Rugo HS, Liu MC, Stearns V, Come SE, Borger DR, Quadrino CA, Finkelstein D, Garber JE, Ryan PD, Winer EP, Ellisen LW
TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. J Clin Oncol. 2011 May 20; 29(15_suppl):1025.
TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response.
Ruddy KJ, Gelber S, Tamimi RM, Ginsburg ES, Schapira L, Come SE, Meyer ME, Winer EP, Partridge AH
Fertility concerns in young women with breast cancer: Results from a prospective cohort study. J Clin Oncol. 2011 May 20; 29(15_suppl):6025.
Fertility concerns in young women with breast cancer: Results from a prospective cohort study.
Morris PG, Patil S, Chen C, Abbruzzi A, Lehman RJ, Steingart R, Oeffinger KC, Lin NU, Moy B, Come SE, Winer EP, Norton L, Hudis C, Dang CT
Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC). J Clin Oncol. 2013 Sep 10; 31(26_suppl):167.
Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).
Eastman RC, Come SE, Strewler GJ, Gorden P, Kahn CR
The Journal of clinical endocrinology and metabolism
Adriamycin therapy for advanced insulinoma. J Clin Endocrinol Metab. 1977 Jan; 44(1):142-8.
Adriamycin therapy for advanced insulinoma.
Howell A, Pippen J, Elledge RM, Mauriac L, Vergote I, Jones SE, Come SE, Osborne CK, Robertson JF
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer. 2005 Jul 15; 104(2):236-9.
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.
Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8340-7.
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.
Dubey A, Recht A, Come SE, Gelman RS, Silver B, Harris JR, Shulman LN
Concurrent CMF and radiation therapy for early stage breast cancer: results of a pilot study. Int J Radiat Oncol Biol Phys. 1999 Nov 01; 45(4):877-84.
Concurrent CMF and radiation therapy for early stage breast cancer: results of a pilot study.
Gage I, Schnitt SJ, Recht A, Abner A, Come S, Shulman LN, Monson JM, Silver B, Harris JR, Connolly JL
Skin recurrences after breast-conserving therapy for early-stage breast cancer. J Clin Oncol. 1998 Feb; 16(2):480-6.
Skin recurrences after breast-conserving therapy for early-stage breast cancer.
Bellon JR, Shulman LN, Come SE, Li X, Gelman RS, Silver BJ, Harris JR, Recht A
A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma. Cancer. 2004 Apr 01; 100(7):1358-64.
A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma.
Harris JR, Recht A, Connolly J, Cady B, Come S, Henderson IC, Koufman C, Love S, Schnitt S, Osteen R
Conservative surgery and radiotherapy for early breast cancer. Cancer. 1990 Sep 15; 66(6 Suppl):1427-38.
Conservative surgery and radiotherapy for early breast cancer.
Dubey AK, Recht A, Come S, Shulman L, Harris J
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
Why and how to combine chemotherapy and radiation therapy in breast cancer patients. Recent Results Cancer Res. 1998; 152:247-54.
Why and how to combine chemotherapy and radiation therapy in breast cancer patients.
Robertson JF, Come SE, Jones SE, Beex L, Kaufmann M, Makris A, Nortier JW, Possinger K, Rutqvist LE
European journal of cancer (Oxford, England : 1990)
Endocrine treatment options for advanced breast cancer--the role of fulvestrant. Eur J Cancer. 2005 Feb; 41(3):346-56.
Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brodie AM, Colditz GA, Johnston SR, Kristensen VN, Lønning PE, McDonnell DP, Osborne CK, Russo J, Santen RJ, Yee D, Hart CS
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):861s-4s.
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
Role of fulvestrant in sequential hormonal therapy for advanced, hormone receptor-positive breast cancer in postmenopausal women. Clin Breast Cancer. 2005 Apr; 6 Suppl 1:S15-22.
Role of fulvestrant in sequential hormonal therapy for advanced, hormone receptor-positive breast cancer in postmenopausal women.
Ensminger WD, Rosowsky A, Raso V, Levin DC, Glode M, Come S, Steele G, Frei E
A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. Cancer Res. 1978 Nov; 38(11 Pt 1):3784-92.
A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil.
Review of gene-expression profiling and its clinical use in breast cancer. Crit Rev Oncol Hematol. 2009 Jan; 69(1):1-11.
Review of gene-expression profiling and its clinical use in breast cancer.
Wheeler CA, Shulman LN, Ervin T, Come SE, Schnipper LE
Cisplatin, continuous-infusion 5-fluorouracil, and intermediate-dose methotrexate in the treatment of unresectable non-small cell carcinoma of the lung. Cancer. 1991 Feb 15; 67(4):892-5.
Cisplatin, continuous-infusion 5-fluorouracil, and intermediate-dose methotrexate in the treatment of unresectable non-small cell carcinoma of the lung.
Catheterization and cardiovascular diagnosis
Use of pulmonary capillary wedge aspirates for the antemortem diagnosis of pulmonary microvascular tumor. Cathet Cardiovasc Diagn. 1989 Jun; 17(2):112-5.
Use of pulmonary capillary wedge aspirates for the antemortem diagnosis of pulmonary microvascular tumor.
Recht A, Come SE, Gelman RS, Goldstein M, Tishler S, Gore SM, Abner AL, Vicini FA, Silver B, Connolly JL
Integration of conservative surgery, radiotherapy, and chemotherapy for the treatment of early-stage, node-positive breast cancer: sequencing, timing, and outcome. J Clin Oncol. 1991 Sep; 9(9):1662-7.
Integration of conservative surgery, radiotherapy, and chemotherapy for the treatment of early-stage, node-positive breast cancer: sequencing, timing, and outcome.
Breast cancer chemotherapy: perioperative considerations in breast reconstruction. Plast Reconstr Surg. 1985 Mar; 75(3):430-4.
Breast cancer chemotherapy: perioperative considerations in breast reconstruction.
Frei E, Garnick MB, Ensminger WD, Israel M, Steele GD, Kaplan WD, Come SE
Biochemical pharmacology in medical oncology. Cancer Treat Rep. 1981; 65 Suppl 3:21-6.
Biochemical pharmacology in medical oncology.
Update: a 62-year-old woman with a new diagnosis of breast cancer. JAMA. 2008 Mar 05; 299(9):1055-6.
Update: a 62-year-old woman with a new diagnosis of breast cancer.
Dang C, Lin N, Moy B, Come S, Sugarman S, Morris P, Abbruzzi A, Chen C, Steingart R, Patil S, Norton L, Winer E, Hudis C
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. J Clin Oncol. 2010 Jun 20; 28(18):2982-8.
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
Kaplan WD, Ensminger WD, Come SE, Smith EH, D'Orsi CJ, Levin DC, Takvorian RW, Steele GD
Radionuclide angiography to predict patient response to hepatic artery chemotherapy. Cancer Treat Rep. 1980; 64(12):1217-22.
Radionuclide angiography to predict patient response to hepatic artery chemotherapy.
A 62-year-old woman with a new diagnosis of breast cancer. JAMA. 2006 Mar 22; 295(12):1434-42.
A 62-year-old woman with a new diagnosis of breast cancer.
Staging in non-Hodgkin's lymphoma: approach, results and relationship to histopathology. Clin Haematol. 1979 Oct; 8(3):645-56.
Staging in non-Hodgkin's lymphoma: approach, results and relationship to histopathology.
Rose MA, Henderson IC, Gelman R, Boyages J, Gore SM, Come S, Silver B, Recht A, Connolly JL, Schnitt SJ
Premenopausal breast cancer patients treated with conservative surgery, radiotherapy and adjuvant chemotherapy have a low risk of local failure. Int J Radiat Oncol Biol Phys. 1989 Oct; 17(4):711-7.
Premenopausal breast cancer patients treated with conservative surgery, radiotherapy and adjuvant chemotherapy have a low risk of local failure.
Harris JR, Recht A, Schnitt S, Connolly J, Silver B, Come S, Henderson IC
Current status of conservative surgery and radiotherapy as primary local treatment for early carcinoma of the breast. Breast Cancer Res Treat. 1985; 5(3):245-55.
Current status of conservative surgery and radiotherapy as primary local treatment for early carcinoma of the breast.
Hardenbergh PH, Recht A, Gollamudi S, Come SE, Hayes DF, Shulman LN, O'Neill A, Gelman RS, Silver B, Harris JR
Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer. Int J Radiat Oncol Biol Phys. 1999 Aug 01; 45(1):69-72.
Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer.
Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002 Aug 15; 20(16):3386-95.
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Surface remodeling vs. whole-cell hemolysis of reticulocytes produced with erythroid stimulation or iron deficiency anemia. Blood. 1974 Dec; 44(6):817-30.
Surface remodeling vs. whole-cell hemolysis of reticulocytes produced with erythroid stimulation or iron deficiency anemia.
Come SE, Buzdar AU, Arteaga CL, Bissell MJ, Brown MA, Ellis MJ, Goss PE, Green JE, Ingle JN, Lee AV, Medina D, Nicholson RI, Santen RJ, Schiff R, Hart CS
Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 2):327S-330S.
Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
Bellon JR, Come SE, Gelman RS, Henderson IC, Shulman LN, Silver BJ, Harris JR, Recht A
Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol. 2005 Mar 20; 23(9):1934-40.
Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial.
Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brown M, Dowsett M, Hilsenbeck SG, Kumar R, Johnston SR, Lee AV, Paik S, Pritchard KI, Winer EP, Hart C
Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):997s-1000s.
Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement.
Elevated creatine kinase and malignancy. Hosp Pract (Off Ed). 1990 Dec 15; 25(12):123, 126, 129-30.
Elevated creatine kinase and malignancy.
Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008 Apr 20; 26(12):1993-9.
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.
Burstein HJ, Mayer E, Patridge AH, O'Kane H, Litsas G, Come SE, Hudis CA, Goldstein DF, Muss HB, Winter EP, Garber JE
Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. Clin Breast Cancer. 2006 Jun; 7(2):158-61.
Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons.
Lin NU, Parker LM, Come SE, Burstein HJ, Haldoupis M, Ryabin N, Gelman R, Winer EP, Shulman LN
Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs. 2007 Aug; 25(4):369-75.
Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions.
Mauch P, Goffman T, Rosenthal DS, Canellos GP, Come SE, Hellman S
Stage III Hodgkin's disease: improved survival with combined modality therapy as compared with radiation therapy alone. J Clin Oncol. 1985 Sep; 3(9):1166-73.
Stage III Hodgkin's disease: improved survival with combined modality therapy as compared with radiation therapy alone.
Chemotherapy in the treatment of Hodgkin's disease. Semin Hematol. 1983 Jan; 20(1):1-24.
Chemotherapy in the treatment of Hodgkin's disease.
Mauch PM, Kalish LA, Marcus KC, Coleman CN, Shulman LN, Krill E, Come S, Silver B, Canellos GP, Tarbell NJ
Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood. 1996 May 01; 87(9):3625-32.
Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome.
Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP
Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1198-207.
Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.
Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer. Expert Opin Drug Saf. 2011 Sep; 10(5):819-26.
Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.
Eder JP, Antman K, Peters W, Henner WD, Elias A, Shea T, Schryber S, Andersen J, Come S, Schnipper L
High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol. 1986 Nov; 4(11):1592-7.
High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer.
Morris PG, Dickler M, McArthur HL, Traina T, Sugarman S, Lin N, Moy B, Come S, Godfrey L, Nulsen B, Chen C, Steingart R, Rugo H, Norton L, Winer E, Hudis CA, Dang CT
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol. 2009 Dec 20; 27(36):6117-23.
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.
Sheldon T, Hayes DF, Cady B, Parker L, Osteen R, Silver B, Recht A, Come S, Henderson IC, Harris JR
Primary radiation therapy for locally advanced breast cancer. Cancer. 1987 Sep 15; 60(6):1219-25.
Primary radiation therapy for locally advanced breast cancer.
Paradoxical emetic response to antiemetic treatment in cancer patients. N Engl J Med. 1980 Dec 18; 303(25):1480.
Paradoxical emetic response to antiemetic treatment in cancer patients.
Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, Brachtel EF, Schapira L, Come SE, Winer EP, Partridge AH
Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat. 2012 Feb; 131(3):1061-6.
Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer.
Abner AL, Collins L, Peiro G, Recht A, Come S, Shulman LN, Silver B, Nixon A, Harris JR, Schnitt SJ, Connolly JL
Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma. Cancer. 1998 Dec 15; 83(12):2502-8.
Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma.
Lion J, Henderson M, Malbon A, Bergman A, Come S
Case mix and charges for inpatient and outpatient chemotherapy. Health Care Financ Rev. 1987; 8(4):65-71.
Case mix and charges for inpatient and outpatient chemotherapy.
Abner AL, Recht A, Vicini FA, Silver B, Hayes D, Come S, Harris JR
Cosmetic results after surgery, chemotherapy, and radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys. 1991 Jul; 21(2):331-8.
Cosmetic results after surgery, chemotherapy, and radiation therapy for early breast cancer.
Rosen EM, Goldberg ID, Rose C, Come S, Goldstein M, Simon L, Botnick LE
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Sequential multi-agent chemotherapy and whole abdominal irradiation for stage III ovarian carcinoma. Radiother Oncol. 1986 Nov; 7(3):223-31.
Sequential multi-agent chemotherapy and whole abdominal irradiation for stage III ovarian carcinoma.
Kuribayashi S, Phillips DA, Harrington DP, Bettmann MA, Garnic JD, Come SE, Levin DC
Therapeutic embolization of the gastroduodenal artery in hepatic artery infusion chemotherapy. AJR Am J Roentgenol. 1981 Dec; 137(6):1169-72.
Therapeutic embolization of the gastroduodenal artery in hepatic artery infusion chemotherapy.
Beadle GF, Come S, Henderson IC, Silver B, Hellman S, Harris JR
The effect of adjuvant chemotherapy on the cosmetic results after primary radiation treatment for early stage breast cancer. Int J Radiat Oncol Biol Phys. 1984 Nov; 10(11):2131-7.
The effect of adjuvant chemotherapy on the cosmetic results after primary radiation treatment for early stage breast cancer.
Come SE, Buzdar AU, Arteaga CL, Brodie AM, Davidson NE, Dowsett M, Ingle JN, Johnston SR, Lee AV, Osborne CK, Pritchard KI, Vogel VG, Winer EP, Hart CS
Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):443S-6S.
Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement.
Mauch PM, Kalish LA, Marcus KC, Shulman LN, Krill E, Tarbell NJ, Silver B, Weinstein H, Come S, Canellos GP, Coleman CN
The cancer journal from Scientific American
Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am. 1995 May-Jun; 1(1):33-42.
Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease.